Sulbenicillin was synthesized by Takeda Chemical Industries in 1968. It shows slightly lower activity against gram-positive bacteria, almost the same activity against gramnegative bacteria, and slightly higher activity against anaerobic bacteria in comparison with carbenicillin. Sulbenicillin has been used by intravenous and intramuscular administration for therapy of sepsis, bacterial endocarditis, pyoderma, urinary tract and respiratory tract infections, and other infections caused by Staphylococcus, Streptococcus, Klebsiella, Proteus, Enterobacter, Citrobacter, Escherichia coli and Haemophilus influenzae.
